Photo: University of Kentucky's College of Agriculture, Food, and Environment

The University of Kentucky (UK) Gluck Equine Research Center recently welcomed back Allen Page, DVM, PhD, as a scientist and veterinarian. Page completed his doctoral degree in the UK Department of Veterinary Science in 2013.

Page said he decided to come back in April after working for the USDA for more than two years because he enjoyed the collaboration with colleagues he previously worked with during his previous five years at the Gluck Center. He particularly enjoyed the challenge of research that the Gluck Center has to offer.

I think that as somebody who has been working with horses my whole life, it is something that interests me as of means of helping the horses and owners from a welfare aspect and performance aspect, he said.

In his multifaceted role at the Gluck Center, Page works as a scientist and veterinarian working with David Horohov, PhD, chair of the Department of Veterinary Science and director of the Gluck Equine Research Center. Page manages the laboratory and is also the departments clinical veterinarian, a role that has him oversee the veterinary care of the departments 300 horses. He also has a small appointment working for the universitys attending veterinarian and serves as an alternate member on the Institutional Animal Care and Use Committee, where he will help review protocols and conduct site inspections for research projects.

Before he left UK, Page was involved in a study examining inflammation in racehorses and picked up the research when he returned. He and others in the laboratory are trying to develop an easy-to-run test that will give veterinarians and researchers an idea whether horses could be at risk for injury. The laboratory has also used the test to look at young horses, primarily 2-year-olds in training, to determine how fit they are and if they are responding appropriately to increased training. This is important to the industry because it could potentially help prevent horses from suffering career- and life-ending injuries.

Page recently completed a preliminary collaborative project with researchers from Lincoln Memorial University (LMU), in Harrogate, Tennessee, where they examined the effect of stabling versus pasture management on horses and the effect the management protocols had on lipids or surfactant (the material that lines the alveoli, or air sacs of the lungs) in their lungs. Future collaborative studies with LMU hope to look at the effects of long-term stabling with horses with asthma. This research is important to the industry because barns are typically dusty, dirty, and can exacerbate asthma in those horses.

He is also currently overseeing a pilot study looking at the longevity and the effect of different equine herpesvirus-1 (EHV-1) vaccines on the immune response in horses. Because it can cause abortions in pregnant mares and potentially deadly neurologic deficits all horses, EHV is a disease of interest to many in the equine industry. Page and colleagues are studying the duration of immunity and how long horses white cells (immune cells) will appropriately respond after being challenged with EHV-1.

Page has a bachelors degree in animal science and veterinary degree from University of California, Davis. He completed a yearlong internship with Hagyard Equine Medical Institute, in Lexington, Kentucky, after he graduated from veterinary school. He then came to UK and completed his doctoral degree and postdoctoral studies where his efforts primarily involved work with Lawsonia intracellularis, a bacterial disease of weanling and yearling horses.

Katie Lampert is a marketing and communications intern at the UK Gluck Equine Research Center.

Want more articles like this? Sign up for the Bluegrass Equine Digest e-Newsletter.

More information on Gluck Equine Research Center and UK Ag Equine Programs.

See original here:
Page Rejoins UK Gluck Center's Immunology Group - TheHorse.com

UNIVERSITY PARK, Pa. Alex Barna, a junior from Aliquippa, Pennsylvania, has known that he wanted to be a doctor since the 7th grade. He came to Penn State with an interest in microbiology but discovered an opportunity to distinguish himself from other pre-med students in the College of Agricultural Sciences' immunology and infectious disease major.

Immunology and infectious disease students learn how the body copes with bacterial, viral or parasitic infections, cancer and other diseases. Penn State is one of only five institutions in the United States to offer an immunology major and the only one that blends the study of molecular and cellular immunology with epidemiology of infectious diseases. Barna, a third-generation Penn Stater whose grandfather also was a College of Agricultural Sciences student, says he chose the major because it seemed like a unique opportunity to study what he is interested in while preparing for medical school.

Barna hopes that his experiences will help him become not only a good doctor, but a healthcare professional with a view wider than a single patient. "A lot of doctors are being taught how to treat one patient," he said. "They can find a disease and cure what's happening, but they kind of lack the knowledge to understand populational health."

Since January, Barna has been performing undergraduate research to complement his studies. The lab he works in studies an infectious fungus that affects ants and alters their behavior so that they spread the infection to plant hosts and other ants. Barna is interested in understanding why only 10 percent of ants die when a colony becomes infected. Observing the spread of the disease through these animals is an opportunity to directly observe the populational health dynamics he has learned about in class.

He also is pursuing the selective global health minor through the College of Health and Human Development. Through this minor, he will study abroad next summer somewhere in Africa, shadowing physicians to gain an understanding of the differences and similarities between African and American healthcare.

In addition to his academic pursuits, Barna is excelling in a completely different passion music. He is a singer with Essence of Joy, a choir at Penn State dedicated to singing and preserving African-American music. "Music always has been a really huge part of my life, and I knew I didn't want to lose that coming to college, so I really made an effort to keep it a part of me," he explained.

He also is taking voice lessons for credit and has been studying with Blythe Walker, a singer with the Metropolitan Opera in New York City. "It's been really cool to learn how to sing classical music with someone who lives classical music and really understands the background and importance of it," he said.

Barna is a member of Ag Advocates, a group of high-achieving students in the college who help put together events, assist with prospective students, alumni and donors, and are overall advocates for the college. He also was one of the executive board members for Ag Day, a day for College of Agricultural Sciences clubs and organizations to advertise to the university the impact that agriculture has on everyday life.

He is part of the Tri Beta biological honor society, a national honor society to support excellence in biology and biological sciences, and has served on a Penn State Reads executive committee, where he helped plan for events related to the Penn State Reads book.

Excerpt from:
Medicine and music: Immunology major makes his own way at Penn State - Penn State News

An Update on Merck after 2Q17: Keytruda, Januvia, and Janument PART 9 OF 11

In 2Q17, Mercks (MRK) Remicade generated revenues of around $208 million, which reflected an ~39% decline on a year-over-year (or YoY) basis and a 9% decline on a quarter-over-quarter basis. Merck commercializes Remicade in Europe, Russia, and Turkey.

In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline YoY. Merck estimated that the foreign exchanges benefited the company by ~3% in both 2Q17 and 1H17. The company lost its market exclusivity in major European markets in 2015. Merck does not have market exclusivity for Remicade in any territories.

In July 2017, the FDA approved Mercks Renflexis, a biosimilar of Remicade (infliximab). Merck has launched the product in the US market. The regulatory approval and launch of Renflexis could boost Mercks Immunology segment.

In 2Q17, Mercks Simponi generated revenues of around $199 million, which reflected 8% growth on a quarter-over-quarter basis. In 2Q16, Simponi generated revenues of ~$199 million. In 1H17, Simponi generated revenues of ~$383 million, which represented an ~1% decline YoY. In 2Q17 and 1H17, unfavorable foreign exchange affected revenues by 3% and 4%, respectively.

Mercks peers in the immunology drugs market include AbbVie (ABBV), Amgen (AMGN), Biogen, Pfizer (PFE), and Roche. To read more about Mercks Immunology portfolio, please refer toInside Mercks Immunology Portfolio.

In 2Q17, Mercks Emend generated revenues of around $143 million, which reflects ~8% growth on a quarter-over-quarter basis. In 2Q16, Emend generated revenues of ~$143 million. The higher sales volume in Japan was primarily attributed to the revenue growth in the quarter, which was counterbalanced by a decline in sales volumes in the US market. In 1H17, Emend reported revenues of around $276 million, which is ~3% growth on a YoY basis.

In 2Q17, Temodar reported revenues of around $65 million, which is an 11% decline YoY and 2% growth on aquarter-over-quarter basis. To learn more about Mercks Emend and Temodar, please readHow Mercks Oncology Drugs Emend and Temodar Could Perform in 2017.

Merck comprises ~4.6% of the PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP).

See the original post:
A Look into Merck's Immunology and Oncology Portfolio - Market Realist

Eli Lilly will use Topas Therapeutics antigen-specific tolerance induction platform to develop new treatments, with an initial focus on external antigens believed to induce inflammation and/or autoimmune disease, Topas said today.

The companies have signed a multiyear research and option agreement whose value was not disclosed.

Topas did say, however, that it will receive from Lilly R&D funding and payments tied to unspecified future success of compounds to be in-licensed by Lilly. The pharma giant has been granted an option for all candidates produced under the collaboration for in-licensing and further development, while Topas has agreed to conduct preclinical proof-of-principle studies with Lilly to generate the drug candidates.

Topas says its platform is designed to induce antigen-specific immune tolerance by harnessing the liver's natural immunology capabilities. Through the platform, peptide-loaded nanoparticles are selectively targeted toward liver sinusoidal endothelial cells (LSECs), where tolerance against bloodborne antigens is induced by the generation of peptide-specific regulatory T cells.

We expect this work to support the value of our approach in inducing tolerance also against external antigens, Timm Jessen, Ph.D., CEO of Topas Therapeutics, said in a statement. Additionally, the interest from such an important pharmaceutical company in our technology, we believe, supports the strong commercial potential of our work.

Based in Hamburg, Germany, Topas was spun out of Evotec last year to develop nanoparticle-based therapeutics for immunological disorders. Evotec joined Epidarex Capital, EMBL Ventures, and Gimv in raising 14 million ($16.5 million) in Series A financing for the new company, with proceeds intended to expand and accelerate the platform and advance treatment candidates for multiple autoimmune and inflammatory indications.

See more here:
Lilly to Use Topas Platform in Immunology Collaboration - Genetic Engineering & Biotechnology News

Exposure to air pollution could make people more vulnerable to infection, scientists at a Scottish university have claimed.

A team led by immunology expert Dr Peter Barlow has produced research that suggests particles found in traffic fumes can damage the immune systems ability to kill viruses and bacteria.

Particles found in traffic fumes can damage the immune systems ability to kill viruses, a study has suggested

The work carried out by scientists at Edinburgh Napier University is the first to show this effect and its significant human health implications, the researchers claim.

The Edinburgh Napier study focused on antimicrobial peptides, tiny molecules found in the immune systems of humans and animals which increase in response to infection.

Researchers at the School of Applied Sciences suggested peptides have virus-killing properties which could prove crucial in developing a cure for the common cold.

However, the paper published last week in The Journal of Immunology, suggests that particles found in air pollution can prevent peptides working properly.

Study Director Dr Barlow and researcher Dr Fern Findlay, working in collaboration with the US Centres for Disease Control and Prevention, and the Midlothian-based Moredun Research Institute, found carbon particles could trigger changes in the antimicrobial peptides, potentially resulting in an increased susceptibility to infection.

According to the researchers, the implications are profound for people living in areas of high air pollution, who breathe in high concentrations of particles every day or absorb them through skin contact, especially those with pre-existing lung conditions like asthma or COPD.

Dr Barlow, Associate Professor of Immunology & Infection at Edinburgh Napier, said: This is an area of research that is very poorly understood.

Dr Peter Barlow, senior lecturer, School of Applied Sciences

We were extremely concerned when we found that air pollution particles could inhibit the activity of these molecules, which are absolutely essential in the fight against infection.

In light of these findings, we urge that strong action plans are put in place to rapidly reduce particulate air pollution in our towns and cities.

Commenting on the study, Dr Sheena Cruickshank of the British Society for Immunology, and Senior Lecturer in Immunology at the University of Manchester, said: This interesting study shows that incubation of carbon nanomaterials can inhibit the function of one of our anti-bacterial peptides. However it is not clear how the carbon nanomaterials reflect our physiological exposure to the complex cocktail of pollutants (which include particulate matter (PM2.5 and PM10) such as sulphur dioxide, nitrogen oxide particles and carbon monoxide) as the work was purely done in cell model systems.

Furthermore, the immune system has multiple layers of defence, including other anti-bacterial products and a variety of effector cells, and only one anti-bacterial product is assessed in this paper; therefore much more work needs to be done to assess the significance of this finding. However, this is an interesting, albeit relatively preliminary, study that suggests this is an important research area which should be investigated further.

See the article here:
Pollution raises infection risk, research suggests - AirQualityNews

Immunology is the branch of biomedical science that deals with the response of an organism to antigenic challenge and its recognition of what is self and what is not. It deals with the defence mechanisms including all physical, chemical and biological properties of the organism that help it to combat its susceptibility to foreign organisms, material, etc.

The immune system is divided into those which are static, or innate to the organism, and those which are responsive, or adaptive to a potential pathogen or foreign substance.

The innate system of immunity is on evolutionary terms, the older system that forms the first line of defence. It is non-specific and the resistance is static (it does not improve with repeated exposure and there is no memory on subsequent exposures). This includes physical defences such as skin & epithelial surfaces, cilia, commensual flora, acidic gastric contents, fever etc. Others are biochemical defences such as soluble - lysosyme, acute phase reactants and complement, fibronectin, interferons. Cellular components include natural killer cells, RES phagocytes.

The adaptive system is the second line of defence and is activated once the innate system has been overwhelmed. It is specific to the infective agent and can store the information about the invader as memory to show an enhanced response to subsequent challenge.

Immunology deals with physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders like allergies, hypersensitivities, immune deficiency, transplant rejection and autoimmune disorders.

Immunology deals with physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo. Immunology has a vast array of uses in several disciplines of science and medical science.

The word immunity was derived from the Lain word immunis meaning exempt.

The key primary lymphoid organs of the immune system are thymus andbone marrow, and secondary lymphatic tissues such as spleen, tonsils, lymph vessels,lymph nodes, adenoids, and skin.

In good health thymus, spleen, portions of bone marrow, lymph nodes and secondary lymphatic tissues can be surgically removed without much harm to humans.

The actual components of the immune system are cellular in nature and not associated with any specific organ. They are widely present in circulation throughout the body.

Reviewed by April Cashin-Garbutt, BA Hons (Cantab)

View original post here:
What is Immunology?

A biomedical conference that is held once a decade in Vermont began this afternoon in Burlington.

The Northeast Regional IDeA Conference is bringing more than 300 biomedical researchers to Vermonts largest city to review research, gain collaborative opportunities and meet with National Institutes of Health officials.

The Institutional Development Awards from the NIH target smaller rural states, according to Vermont Genetics Network and UVM Biology professor Judith Van Houten, a conference co-coordinator. This is a coming together of all the funded faculty and students in what NIH calls the Northeast IDeA region. And that means Vermont, New Hampshire, Maine, Rhode Island and Delaware. Not every state is an IDeA state. There are some themes that come out of this. You can always find neuroscience or immunology, bioinformatics but there isnt one grand theme.

While there are sessions on scientific research in areas such as genetics, cancer, and infectious diseases, meetings also touch on careers, writing, patents and grant applications. Van Houten says one of the aims of IDeA is to help scientists in the region become more competitive. Theres a big emphasis on careers and mentoring and getting people into the funding stream. So well have a grant specialist from NIH working with us and well have staff from NIH. So a lot of what we do is mentoring.

The NIH Northeast Regional conference brings together researchers from designated Centers of Biomedical Research Excellence from Maine, New Hampshire, Rhode Island, Delaware and Vermont. Conference co-coordinator Dr. Ralph Budd, the director of the Vermont Center for Immunology and Infectious Diseases, says the agenda reflects the biomedical research occurring in each state. Each of those may have a theme very different from the one we have here in infectious disease and immunology. Theres one with cancer, ones in cardiovascular disease and so on. And so thats why youre seeing a broad array of biomedical research because each of those centers has its own theme. And its a chance to do many things. Its a chance to obviously exchange scientific ideas and to form collaborations. Truth be known you know when you get someone from immunology talking with someone from infectious disease talking with someone from cancer biology over a cup of coffee theyre going to find common ground. And thats what this is about.

The regional conference rotates biennially in each state. During the off years, national meetings are held in Washington, D.C.

Read the rest here:
Biomedical Conference Begins In Burlington - WAMC

Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical Trial Project ORCA: Leverages a New Immuno-Oncology Antibody Target Based on Physiocrine Biology

SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced operating results for the second quarter ended June 30, 2017.

During the first half of 2017, our team advanced three innovative, first-in-class biologics that harness Physiocrine biology in immunology, said John Mendlein, Ph.D., CEO of aTyr Pharma. For our Resolaris program, we report favorable safety data from two extension studies in patients with rare muscular dystrophies underscoring the potential for improved clinical outcomes over time based on stabilizing or improving muscle function. In addition, we plan to initiate our first-in-human clinical trial for our iMod.Fc program for ILD. Our third program, ORCA targets a novel, proprietary immuno-oncology pathway using antibodies to change levels of Resokine in tumor settings. We believe tumors utilize Resokine to evade immune system responses. Our Resolaris, iMod.Fc and ORCA programs demonstrate the power and leverage arising from our new insights in immunology and novel therapeutic modalities targeting homeostatic pathways.

Resolaris Program First Resokine Therapeutic Candidate Based on a Protein Secreted by Muscle

Safety Extension Study Results (005 and 006) aTyr recently completed two extension studies in patients with limb-girdle muscular dystrophy 2B (LGMD2B), adult facioscapulohumeral muscular dystrophy (FSHD), and early onset FSHD. Per protocol patients received 3.0 mg/kg of Resolaris weekly in these extension studies.

Promising Clinical Results for Resolaris in Early Onset FSHD During the quarter, aTyr announced top-line results from its Phase 1b/2 trial (003) of Resolaris in patients with early onset FSHD. Overall, 63% of patients (5/8) showed an increase from baseline in their MMT score, with a mean change from baseline of +3.8%. Resolaris was generally well-tolerated at doses up to 3.0 mg/kg once weekly in this younger patient population (patients in the trial were between the ages of 16 and 20) with no observed signs of general immunosuppression.

AAN Presentation During the quarter, Dr. John Vissing, M.D., Ph.D., Professor of Neurology, University of Copenhagen, presented a poster titled Results of a Phase 1b/2 Study of ATYR1940 in Adult Patients with Limb Girdle Muscular Dystrophy Type 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (ATYR-C-004) at the American Academy of Neurology (AAN) Annual Meeting on April 25, 2017 in Boston, MA.

Clinical Development Plan Initiation of a randomized placebo-controlled trial with Resolaris is contingent upon the identification of a PD assay and execution of a partnership related to one of our pipeline programs.

iMod.Fc Program First Fc Fusion Based Therapeutic Candidate for Lung Diseases

Clinical Development aTyr Pharma plans to commence a Phase 1 clinical program for the iMod.Fc program later this year. This randomized, double-blind, placebo-controlled study will investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics (PD) of intravenous iMod.Fc in healthy volunteers.

American Thoracic Society (ATS) Presentations During the quarter, aTyr Pharma presented two posters on the iMod.Fc program at the ATS International Conference May 19 - 24, 2017 in Washington, D.C.:

In conjunction with the ATS presentations, aTyr Pharma hosted an educational webinar featuring Dr. Steven D. Nathan, M.D., FCCP, Director of the Advanced Lung Disease Program and Lung Transplant Program at Inova Fairfax Hospital, to provide disease education on interstitial lung diseases that are characterized by an immune component, such as idiopathic pulmonary fibrosis (IPF), sarcoidosis, and chronic hypersensitivity pneumonitis (CHP). The webinar is available on the aTyr Pharma investor website.

Project ORCA First Antibody Antagonist to a Physiocrine Immunology Pathway

New Target in Immuno-Oncology ORCA involves a novel and proprietary target that aTyr believes is active across multiple tumor types.

Timeline aTyr plans to select an antibody as a potential IND candidate in 2017.

Second Quarter 2017 Financial Results

Research and development expenses were $8.4 million and $11.3 million for the quarters ended June 30, 2017 and 2016, respectively. The decrease of $2.9million was due primarily to a $2.2 million decrease related to Resolaris clinical trials costs and $0.6 million decrease related to manufacturing costs incurred in support of Resolaris.

General and administrative expenses were $3.5million and $4.1million for the quarters ended June 30, 2017 and 2016, respectively. The decrease of $0.6 million was due primarily to a $0.4 million reduction in professional fees.

First Half 2017 Financial Results

Research and development expenses were $17.6 million and $23.3 million for the six months ended June 30, 2017 and 2016, respectively. The decrease of $5.7million was due primarily to $4.2 million decrease related to manufacturing costs incurred in support of Resolaris and $2.3 million decrease related to Resolaris clinical trials costs. The decrease was partially offset by an increase of $1.0 million related to research and non-clinical development costs incurred for iMod.Fc.

General and administrative expenses were $7.5 million and $8.2 million for the six months ended June 30, 2017 and 2016, respectively. The decrease of $0.7 million was due primarily to a $0.4 million decrease in professional fees.

Financial Guidance

As ofJune 30, 2017, aTyr had$57.2 millionin cash, cash equivalents and investments and 23.8 million shares of common stock outstanding.

aTyr expects that its cash, cash equivalents and investments will be sufficient to fund its anticipated operations into the third quarter of 2018.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of immunological and physiological pathways. To date, the Company has generated three innovative therapeutic programs based on its knowledge of Physiocrine biology in three different therapeutic areas and three different biologic modalities. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe diseases characterized by immune imbalance for which there are currently limited or no treatment options. For more information, please visit http://www.atyrpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding, the potential and potential therapeutic benefits of Resolaris, iMod.Fc, or potential product candidates from Project ORCA, the ability of the Company to successfully advance its pipeline or product candidates, undertake certain development activities (such as clinical trial enrollment and the conduct of clinical trials) and accomplish certain development goals and the timing of such activities and development goals, the timing of initiation of additional clinical trials, the scope and strength of our intellectual property portfolio, our ability to receive regulatory approvals for, and commercialize, our product candidates and of reporting results from our clinical trials, and our projected cash expenditures reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our Physiocrine-based product candidates, as well as those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2016 and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Read the original:
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology ... - GlobeNewswire (press release)

EAACI StatementThe EAACI community is deeply affected by the recent media reports of the death of a young child undergoing an oral food challenge (OFC) in the United States. Firstly, we wish to express our sincere condolences to Alastair Watson's family.

This is the first fatality reported in relation to OFC's and we await the full facts surrounding Alastair's death. While we wait for further details, this statement hopes to reassure the wider allergy community and to highlight procedures that should be followed by those performing OFC's; the gold standard test for food allergy diagnosis.In this regard EAACI has delivered the Guidelines for Food Allergy Diagnosis and Management in 2014 that should serve as best practice of care.

Food challenges are essential for the effective diagnosis and progress management of food allergies and currently cannot be replaced by skin prick or blood IgE, component or basophil activation testing or allergy testing alone. Patients and families should be informed about the potential risks and appropriate consent should be obtained. The OFC has been used safely for decades Life-threatening and fatal anaphylaxis at OFC's are exceptional if proper process and equipment are put in place by the health care professionals involved in oral food challenges. Reviewing internal procedures, setting, staffing and supervision should be performed on regular basis and on individual basis when needed. Ensuring patients safety is paramount. Protocols should be in place following some international guidance such as PRACTALL summarized in the EAACI Guidelines for Clinical practice on Food Allergy and Anaphylaxis, available for download here.

EAACI Pediatric Section

Go here to read the rest:
European Academy of Allergy and Clinical Immunology ...

Select a major from the list

Accounting

Acting

Actuarial Science

Advertising

Aeronautical and Astronautical Engineering

Aerospace Engineering

African-American Studies

Agricultural Business

Agricultural Sciences

Agriculture and Food Security

Agriculture Production

Air Transportation and Distribution

Alternative Medicine

American Literature

American Sign Language - ASL

American Studies

Animal Science

Animal Services

Anthropology / Archeology

Applied / Commercial Art

Applied Mathematics

Applied Sciences

Architectural History

Architectural Technology

Architecture

Art History

Arts

Asian Studies

Astronomy / Astrophysics

Atmospheric Science

Banking

Biblical Studies

Biochemistry

BioEngineering

Bioinformatics

Biological and Agricultural Engineering

Biology / Biological Sciences

Biomedical and Medical Engineering

Biomedical Sciences

Biophysics

Biotechnology

Bookkeeping

Botany

Business Administration

Business Economics

Business Finance

Business Management

Business Marketing

Cellular Biology and Anatomical Sciences

Ceramic Engineering

Chemical Engineering

Chemistry Sciences

Child Care / Child Psychology

Chinese

Chinese Studies

Chiropractics

Civil Engineering

Classical Studies

Clinical Laboratory Science Professions

Clinical Psychology

Communication Disorders Sciences

Communication Studies

Communication Technology

Comparative Language Studies and Services

Computational Finance

Computer and Information Sciences

Computer Engineering

Computer Programming

Computer Systems Analysis

Construction

Corporate Strategy

Cosmetology and Related Services

Counseling and Guidance

Creative Writing

Criminal Justice, Law Enforcement, and Corrections

Criminology

Culinary Arts and Culinary Services

Cultural Studies

Curriculum and Instruction

Dance

Data Entry Processing

Decision Sciences

Dentistry

Design and Applied Arts

Developmental Psychology

Digital, Radio, and Television Communication

Drafting and Design Engineering

Drama

Earth Science

Ecology and Evolutionary Biology

Economics

Education

Educational Administration and Supervision

Educational Evaluation and Research

Electrical Engineering

Electrical Repair and Maintenance

Electronic Communication System Technology

Electronics

Engineering - Architectural

Read more from the original source:
ALLERGY AND IMMUNOLOGY SPECIALIST - Bangor Daily News